Impax Laboratories Schedules Conference Call And Webcast For Second Quarter 2012 Financial Results

Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that its second quarter 2012 financial results will be released before the market opens on Tuesday, July 31, 2012 and will be available on Impax’s Web site at www.impaxlabs.com. The Company will host a conference call and live webcast with financial analysts at 11:00 a.m., Eastern Time.

The live webcast will be accessible through the Investor Relations section of the company's Web site, www.impaxlabs.com.

To access the call through a conference line, dial (877) 356-3814 (in the U.S.) and (706) 758-0033 (international callers) beginning 10 minutes prior to the scheduled start of the call.

A replay of the conference call will be available for seven days shortly after the call. To access the replay, dial (855) 859-2056 (in the U.S.) and (404) 537-3406 (international callers). The access conference code is 99743725.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax has developed marketing partnerships to fully leverage its technology platform. Impax Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward, Philadelphia and Taiwan facilities. For more information, please visit the Company's Web site at: www.impaxlabs.com.

Copyright Business Wire 2010

If you liked this article you might like

Impax Shares Jump on Merger Buzz

Impax Shares Jump After Chinese Firm Reveals 5% Stake

Teva, Mylan Seen to Stay on M&A Sidelines

Teva's Massive Debt Load Just Became an Even Bigger Issue

Teva Shares Are Getting Obliterated Again After Vicious Investment Bank Downgrades